- Abstract Number: 2500
Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
- Abstract Number: 2045
Descriptive Study on the Use of Serum Levels of Immunoglobulin G4, Immunoglobulin E and Eosinophil Count as Serum Biomarkers Across Four Clinical Phenotypes of IgG4-Related Disease
- Abstract Number: 1894
Detection of Fibrotic Lung Changes and Bronchiectasis in RA Patients Screened for Lung Cancer with Low-dose CT Chest: Results from a Large Multi-hospital System
- Abstract Number: 2566
Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
- Abstract Number: 0970
Deubiquitylase (DUB) BRCC36 Isopeptidase Complex (BRISC) Inhibitors Prevent IFNAR1 Deubiquitination to Restore Natural Type I IFN Response in Autoimmunity
- Abstract Number: 1135
Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
- Abstract Number: 0290
Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program
- Abstract Number: 2056
Deucravacitinib Treatment Did Not Impact Immune Response to SARS-CoV-2 Vaccines and Infection in Patients with Plaque Psoriasis: Results from the Phase 3 POETYK Long-Term Extension Trial
- Abstract Number: 0662
Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial
- Abstract Number: 1137
Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)
- Abstract Number: 1921
Devastating Morbidity and Mortality Rates in the Hmong Population with a Diagnosis of Gout Who Had a COVID-19 Infection
- Abstract Number: 2660
Developing Predictive Models for the Diagnosis of VEXAS Syndrome
- Abstract Number: 2326
Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis
- Abstract Number: 0796
Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases
- Abstract Number: 0316
Development and Evaluation of the Adult-onset Still’s Disease Activity Index Based on Whole RNA-seq Analysis: A Novel Approach Independent of Tocilizumab Treatment
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 181
- Next Page »